12066092

Source:http://linkedlifedata.com/resource/pubmed/id/12066092

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008838, umls-concept:C0009429, umls-concept:C0013089, umls-concept:C0025677, umls-concept:C0042670, umls-concept:C0065452, umls-concept:C0302592, umls-concept:C0332257, umls-concept:C0441769, umls-concept:C0600558
pubmed:issue	6
pubmed:dateCreated	2002-6-14
pubmed:abstractText	The purpose of this study was to determine the survival rates and toxicity levels that are associated with multimodal therapy (including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin [MVAC]) in patients with stage IIB to IVB cervical cancer.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0370476
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate, http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine
pubmed:status	MEDLINE
pubmed:month	Jun
pubmed:issn	0002-9378
pubmed:author	pubmed-author:BoardmanCecelia HCH, pubmed-author:DowdySean CSC, pubmed-author:HartmannLynn CLC, pubmed-author:LongHarry JHJ, pubmed-author:PodratzKarl CKC, pubmed-author:WilsonTimothy OTO
pubmed:issnType	Print
pubmed:volume	186
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1167-73
pubmed:dateRevised	2006-4-24
pubmed:meshHeading	pubmed-meshheading:12066092-Adult, pubmed-meshheading:12066092-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12066092-Cisplatin, pubmed-meshheading:12066092-Combined Modality Therapy, pubmed-meshheading:12066092-Doxorubicin, pubmed-meshheading:12066092-Female, pubmed-meshheading:12066092-Humans, pubmed-meshheading:12066092-Methotrexate, pubmed-meshheading:12066092-Middle Aged, pubmed-meshheading:12066092-Neoplasm, Residual, pubmed-meshheading:12066092-Neoplasm Recurrence, Local, pubmed-meshheading:12066092-Neoplasm Staging, pubmed-meshheading:12066092-Neutropenia, pubmed-meshheading:12066092-Retrospective Studies, pubmed-meshheading:12066092-Survival Analysis, pubmed-meshheading:12066092-Treatment Outcome, pubmed-meshheading:12066092-Uterine Cervical Neoplasms, pubmed-meshheading:12066092-Vinblastine
pubmed:year	2002
pubmed:articleTitle	Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer.
pubmed:affiliation	Section of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
pubmed:publicationType	Journal Article